Study of NT-pro-BNP and Hs-Troponin I Biomarkers for Early Detection of Children’s Heart Function of Protein-Energy Malnutrition

Abstract

The Protein Energy Malnutrition (PEM) is the condition of a lack of carbohydrate and protein stores in the body that trigger chronic failure nutrient intake and body maintenance function caused to impact the heart functions. The NT-pro-BNP and Hs- Troponin I proteins were found as the indicator of cardiac dysfunction. The sixty subjects of PEM, analyzed by standard of Indonesia Healt Ministry as well as nutritional status. The blood electrolytes examined by laboratory assay and the levels of Hs-Troponin 1 and NT-Pro-BNP were analyzed by Immune-Chromatography method. Assessing of the ventricular mass with the seeing the peak of the diastolic flow rate of left ventricular that estimated by the curve of the receiver operating characteristic and the area under the curve (P<0.05). The result has shown that the PEM decreased in the left ventricular mass for impaired heart function and systolic disorder. The Hs- Troponin I (90.9%) has better sensitivity than NT-pro-BNP (85.5%) if the merger of those markers possesses the lowest sensitivity (81.8%). These proteins have good biomarkers in heart function, mainly in cases where PEM is present.

Early marker of left ventricular dysfunction in echocardiography and cardiac biomarkers in sick children with severe acute malnutrition

“…Among these cardiac biomarkers, BNP has established role to recognize ventricular dysfunction irrespective of etiology 9 and cTn-I is considered as gold standard to detect myocardial injury irrespective of etiology. 10 In our study we mentioned that cardiac biomarker like cardiac troponin and BNP 11 would increase in children with SAM. We found that , out of 86 children with SAM, 32 (37.2%) children were increased BNP levels and 46 (53.5%) children had increased cTn-I levels.…”

Cardiac Biomarkers in Patients with COVID-19

“…19 The two important biomarkers known to reflect cardiac injury/cardiac dysfunction include NT-proBNP and hs troponin I. 13 B-type natriuretic peptide, a 32 amino acid polypeptide, contains a 17 amino acid ring structure with two cysteine residue connected by a disulfide bond.…”

“…[24][25][26][27] One of the earlier studies shows that the sensitivity and specificity of troponin can be used for the diagnosis of myocardial damage, whereas that of NT-proBNP can be used for diagnosis and to judge the effectiveness of cardiovascular therapy. 13 The release of NT-proBNP and troponin takes place by the cardiac myocytes in case of increased wall stress due to heart failure and myocardial dysfunction along with other natriuretic peptides. 13,28 Research has shown evidence of CVD to be common comorbidity in COVID-19 patients.…”

“…13 The release of NT-proBNP and troponin takes place by the cardiac myocytes in case of increased wall stress due to heart failure and myocardial dysfunction along with other natriuretic peptides. 13,28 Research has shown evidence of CVD to be common comorbidity in COVID-19 patients. 7 In our study, we have highlighted the cardiac marker levels in COVID-19 patients.…”

“…12 Based on the association of the CVD with COVID-19 infection and the importance of understanding the influence of COVID-19 on the cardiovascular system, we have studied the cardiac makers, N terminal-pro B-type natriuretic peptide (NT-proBNP) and highsensitive troponin I (hs troponin I) in COVID-19 patients. Based on the fact that NT-proBNP and hs troponin I are important indicators of cardiac dysfunction, 13 we aim to study these biomarkers in COVID-19 patients presented with chest pain aiding a better patient care and a better understanding of the cardiac markers in such patients. We have divided the study based on two main objectives:…”